Guardion Health Sciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Guardion Health Sciences Inc (GHSI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Guardion Health Sciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 8M vs 8,478M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-96.2% annualized vs trailing 12 months), vs holding steady (+1.7%) for its tracked peer group.
- Growth: Guardion Health Sciences Inc generated -96.8% revenue growth year over year in Q2 2024, vs -7.2% for its competitors combined.
- Profitability: Its 14,158.8% net margin compares with -5.0% for the peer group.
- Peer revenue share: Guardion Health Sciences Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GHSI Sales vs. its Competitors, Q2 2024
Guardion Health Sciences Inc reported revenue contraction of 96.76 % year on year in Q2 2024, below its competitors' combined revenue change of -7.22 %.
With a net margin of 14,158.82 %, Guardion Health Sciences Inc achieved higher profitability than its competitors (-4.98 %).
Guardion Health Sciences Inc generated 0.00 % of the combined sales of its peer group, down from 0.10 % a year earlier.
API endpoints for this dataset
Guardion Health Sciences Inc vs. its Competitors, Q2 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Guardion Health Sciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Guardion Health Sciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Guardion Health Sciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Guardion Health Sciences Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -96.8% for Guardion Health Sciences Inc. Guardion Health Sciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Guardion Health Sciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Guardion Health Sciences Inc | Yes | No | No | No |
| Competitors combined (7) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 62.50 % (5 of 8) | 0.00 % (0 of 8) | 50.00 % (4 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GHSI Stock Performance relative to its Competitors
GHSI Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Herbalife Ltd | 282.9% | Outperformed |
| 2 | Adamas Trust Inc | 282.9% | Outperformed |
| 3 | Usana Health Sciences Inc | 282.9% | Outperformed |
| 4 | Lifevantage Corp | 282.9% | Outperformed |
| 5 | Nature s Sunshine Products inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Guardion Health Sciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Guardion Health Sciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Guardion Health Sciences Inc |
4.18 | 7.65 |
 Herbalife Ltd |
1,672.81 | 5,277.80 |
 Thorne Healthtech Inc |
548.90 | 255.95 |
 Adamas Trust Inc |
492.00 | 240.05 |
 Usana Health Sciences Inc |
242.17 | 912.70 |
 Nature s Sunshine Products inc |
200.42 | 491.79 |
| SUBTOTAL | 3,414.24 | 8,741.50 |
Sign in to see all competitors of Guardion Health Sciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Guardion Health Sciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Guardion Health Sciences Inc's Competitors Named by the Company
Competitive relationships identified from Guardion Health Sciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Herbalife Ltd | Company report | 85% |
| Lifevantage Corp | Company report | 85% |
| Usana Health Sciences Inc | Company report | 85% |
| Nature s Sunshine Products inc | Company report | 85% |
| Thorne Healthtech Inc | Company report | 85% |
| Nu Skin Enterprises Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Guardion Health Sciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Guardion Health Sciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Usana Health Sciences Inc | Core nutritional 81.83 % |
| Nature s Sunshine Products inc | Asia 47.22 % |
| Nu Skin Enterprises Inc | Manufacturing Segment 18.27 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Guardion Health Sciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Guardion Health Sciences Inc | 4 | - | - |
| Herbalife Ltd | 1,673 | 620,918 | 21,012 |
| Thorne Healthtech Inc | 549 | 1,267,068 | 97,966 |
| Adamas Trust Inc | 492 | 1,086,190 | 35,131 |
| Usana Health Sciences Inc | 242 | 581,339 | -18,630 |
| Nature s Sunshine Products inc | 200 | 610,161 | 23,206 |
| PEERS TOTAL | 3,410 | 609,821 | -1,097 |
Sign in to see all peers for Guardion Health Sciences Inc .
Guardion Health Sciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Herbalife Ltd | Others 35.81 % |
| Thorne Healthtech Inc | Domestic 89.94 % |
| Usana Health Sciences Inc | Greater China 49.38 % |
| Nature s Sunshine Products inc | All Other 31.80 % |
| Lifevantage Corp | US 74.57 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Guardion Health Sciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 52.63 % | 37.92 % (avg) | +14.7 pp |
| Operating Margin | -62.69 % | industry median | +19.8 pp |
| EBITDA Margin | -81.15 % | -6.30 % (avg) | -74.8 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.51 % (avg) | -7.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Guardion Health Sciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.8x | 26.5x | -24.7x |
| EV / EBITDA | - | 15.4x | - |
| P/B | 1.4x | 4.2x | -2.9x |
| Return on Equity | 77.24 % | industry aggregate | 64.92 % |
| Return on Invested Capital | -24.41 % | -9.78 % (avg) | -14.63 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Guardion Health Sciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue Growth | 115.42 % | -4.16 % | 109.30 % | 282.74 % | 28.72 % | 7.20 % |
| Operating Margin | -652.09 % | -1,162.53 % | -452.51 % | - | - | -43.45 % |
| Return on Invested Capital | -151.08 % | -76.08 % | -36.94 % | -34.87 % | -46.82 % | -22.43 % |
| P/E | - | - | - | - | - | 49.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Guardion Health Sciences Inc's Strategic Group Map
Guardion Health Sciences Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Guardion Health Sciences Inc's trailing-12-month revenue growth of -18.6% and operating margin of -62.7% compares with an average of -2.1% growth and -60.3% margin across its 8 closest peers by combined growth, margin and ROIC -- Guardion Health Sciences Inc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Guardion Health Sciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Guardion Health Sciences Inc's dedicated Suppliers and Customers pages, not here.
Guardion Health Sciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Guardion Health Sciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Guardion Health Sciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 19.8 points above the industry median.
- Return on equity 64.9 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-96.2% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Guardion Health Sciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Guardion Health Sciences Inc | 6.97 | 10.20 | - |
| Herbalife Ltd | 0.39 | 1.19 | - |
| Thorne Healthtech Inc | 0.55 | 2.98 | 0.08 |
| Adamas Trust Inc | 0.14 | 1.73 | 2.18 |
| Usana Health Sciences Inc | 1.35 | 2.40 | 0.01 |
| Nature s Sunshine Products inc | 1.19 | 2.39 | - |
Sign in to see all peers for Guardion Health Sciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Guardion Health Sciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Guardion Health Sciences Inc | Q2 2024 | -96.8 % | - |
| Herbalife Ltd | Q3 2026 | +6.0 % | +36.4 % |
| Thorne Healthtech Inc | Q2 2023 | +33.1 % | - |
| Adamas Trust Inc | Q3 2026 | - | - |
| Usana Health Sciences Inc | Q2 2026 | -5.3 % | - |
| Nature s Sunshine Products inc | Q2 2026 | +2.3 % | -35.9 % |
| PEERS TOTAL | -13.9 % | - |
Sign in to see all peers for Guardion Health Sciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Guardion Health Sciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Guardion Health Sciences Inc | Q2 2024 | -57.8 % | - |
| Herbalife Ltd | Q3 2026 | +7.8 % | -11.1 % |
| Thorne Healthtech Inc | Q2 2023 | +29.8 % | +999.2 % |
| Adamas Trust Inc | Q3 2026 | - | -45.6 % |
| Usana Health Sciences Inc | Q2 2026 | -3.3 % | -37.2 % |
| Nature s Sunshine Products inc | Q2 2026 | -3.7 % | +105.6 % |
Sign in to see all peers for Guardion Health Sciences Inc .
Guardion Health Sciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Guardion Health Sciences Inc | 50.49% | 55.97% | 77.24% |
| Herbalife Ltd | 6.26% | 8.15% | - |
| Thorne Healthtech Inc | 8.38% | 9.11% | 13.58% |
| Adamas Trust Inc | 0.06% | 0.08% | 0.55% |
| Usana Health Sciences Inc | - | - | - |
| Nature s Sunshine Products inc | 7.14% | 9.91% | 11.26% |
Sign in to see all peers for Guardion Health Sciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Guardion Health Sciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Guardion Health Sciences Inc | 0.66 | 0.55 |
| Herbalife Ltd | 9.17 | 0.32 |
| Thorne Healthtech Inc | 26.82 | 2.14 |
| Adamas Trust Inc | - | 2.05 |
| Usana Health Sciences Inc | - | 0.27 |
| Nature s Sunshine Products inc | 10.93 | 0.41 |
| PEERS AVERAGE | - | 0.39 |
Sign in to see all peers for Guardion Health Sciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.